Non-opioid drug developer snags PhIII funds; aTyr and Spruce line up capital
A biotech looking to create a non-opioid back pain med has reeled in more financing.
Spine BioPharma put together a $13 million convertible note from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
